Sofinnova Partners and Earlybird Venture Capital led a $65m Series A round in Haya Therapeutics.

Sofinnova Partners, an independent venture capital firm, and Earlybird Venture Capital, a venture capital investor, led a $65m Series A round in Haya Therapeutics SA, a biotechnology company, with participation from Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest and Schroders Capital. "This is a defining moment for HAYA as we are advancing our lead program into the clinic. We are excited that Sofinnova Partners, Earlybird and our syndicate of investors share our vision for the potentially industry changing nature of our platform as we move beyond traditional approaches by leveraging novel therapeutic targets emerging from the regulatory genome," Samir Ounzain, HAYA Therapeutics Co-Founder and CEO.